篮球竞彩哪个软件好 :CIMSՓĵ

򾺲 www.fasfz.com  

ם_ίҕ񽛼׵įЧ^

ע⣺ՓڡRˎ200303 2003 Vol.24 No.3 P.141-144l
ʹՈעՓij̎
R ۸Դ
ڶ܊tWLtԺ񽛃ȿ,Ϻ,200003

ժҪĿģ^׻_ίNMO԰l˵RЧ21R_\NMO԰lIJˑü׻1000mgo3Ȼļ׻80 mgo3ԏ30 mgڷһƒupͣˎBarthelָԺ3ί15ճMurýҕ팦ίǰͬrgȵҕMб^Y21˽^׻_ί17˯Ч@ռ80.9%ճõ@ 4ίoЧԺ3Barthel ָucί15Ŀu@e21ίҕcίǰ@ĸYՓ׻_NMO˵ļ԰lίЧ
PI~: ҕ񽛼; ׻; Barthel ָu

High-dose methylprednisolone in the treatment of patients with neuromyelitis optica: a clinical trial

He bin, Shao-fu yuan.
Department of neurology, Changzheng hospital, Second Military Medical University, Shanghai, China. 200003,


Abstract :
Objective: To observe the clinical effects of high-dose methylprednisolone in the treatment of the acute attacks of neuromyelitis optica(NMO). Method: 21 clinically confirmed NMO patients with acute attacks were treated with high-dose methylprednisolone , 1000mg, intravenously, once a day, for 3 consecutive days. Then, methylprednisolone , 80mg, was used intravenously, one time per day, for another 3 days. Finally, prednisolone, 30mg, was administered orally to the patients everyday and grdually withdrawn within a month. Barthel index score was employed to evaluate the activities of daily life of the patients in the 3rd day after admission and in the 15th day after the drug treatment. The near visual acuity was checked to contrast the visual loss of the patients before the drug therapy with that after the therapy. Result: 80.9%(17/21) percent of patients were responsive excellently to the high-dose methylprednisolone therapy, whose activities of daily life scores improved remarkablely. 4 patients showed no response to the therapy. The Barthel index scores of patients in the 15th day after the drug therapy had more significant improvement than those in the 3rd day before the therapy. The visual acuity of the patients increased more significantly after the drug therapy than that before the therapy. Conclusion: The high-dose methylprednisolone therapy was effective to the acute attack of the patients with NMO.
Key word: neuromyelitis optica; methylprednisolone; Barthel index score

ߺ飺R:RTʿо,t,ИϵyװY˯ϵKXѪeо.@"׌LǪ",ڶ܊tW"A"̆TQ̖.

īI

1Hutchinson O, Solomon T, Moots RJ. Devic's neuromyelitis optica: a primary autoimmune disease.Rheumatology, 2000, 39(2): 215-217
2Thompson A J, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS.Neurology, 1989, 39(7): 369-371
3ݹʝi,x,O,.׻_ίԼо.R񽛲Ws־,2000,13(1):55-56
4݄yt,Y,,.ҕ񽛼ǷǶlӲһ.R񽛲Ws־,1999,12(5):277-279
5Wingerchuk DM, Hogancamp WF, O'Brien PC,et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology, 1999, 53(9): 1107-1114
6Kaufman KI, Trobe JD, Eggenberger ER, et al.Practice parameter: The role of corticosteroids in the acute monosymptomatic optic neuritis. Reports of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000, 54(11 ): 2039-2044
7ꍹ,S.ҕ񽛼(DevicC)RоMչ.tW-񽛲WƌWփ,2001,28(2):90-93
8Mandler RN, Waseem Ahmed, Dencoff JE.Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology, 1998, 51(4): 1219-1220
9Keegan M, Pineda MM, Mc Clelland RL. Plasma exchange for severe attacks of CNS demyelination:predictors of response. Neurology, 2002, 58(1):143-146
10Lucchinetti CF, Mandler RN, Mc Gavern D, et al. A role of humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain, 2002,125(Pt 7): 1425-1427
11,߇.׻_ίҕRЧ^A۵ײs־,1996,12(3):186-187
12Lyons PR, Nevman PK, Saunders M.Methylprednisonlone therapy in multiple sclerosis:A profile of adverse effects. J Neurol Neurosurg Psychiatry, 1988, 51 (2): 285-287

 

1g[PDFʽȫҪʹܛAbode Acrobat(ܛ^󲢳Ҋ,վṩd)

2dՓȫՈcI顱ʹÔcmܛd(24KB)


վ䛵ıߵՓģ

1wTlλ財׃Ķλ\

2Ä񽛼wTlλԴR

357[ԺͽYXĤXҺָ˵ĄӑBо

4жԾƾԼѪY1

554ԼԺ[XĤ׌ָ˵ı^

gӭӑՓlՓļоIĿ
(Ոڰlԕrژ}ʹcuՓĵ}Ŀо@ӷҞg[)

| CIMSՓ | й | ̓M | | Փ | Ŀ_l | WgYԴ | վȫ | MՓľWվȫ |

line.gif (4535 ֹ)

˸õĞҷgӭӱվͶƱ{

򾺲 Ոc

վ򾺲 gӭL

ע⣺վδSDd

All rights reserved, all contents copyright 2000-2019
վ20003¿WL